Lead Product(s) : SK1-I
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enzo’s patent is directed to methods for treating hepatocellular carcinoma, the most common human liver cancer, using the company’s proprietary compound SK1-I and has a term extending into June 2038. Foreign patent applications in the same patent fam...
Product Name : SK1-I
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : SK1-I
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK1-I
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I
Details : The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.
Product Name : SK1-I
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : SK1-I
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK1-I
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Drug Candidate SK1?I shown to markedly decrease lupus-associated immune criteria and kidney inflammation in preclinical study.
Product Name : SK1-I
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2020
Lead Product(s) : SK1-I
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
